Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MIST 
Milestone Pharmaceuticals Inc (MIST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: MIST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.13% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 166.59M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 4 | Beta 0.6 | 52 Weeks Range 0.62 - 2.75 | Updated Date 09/14/2025 |
52 Weeks Range 0.62 - 2.75 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.33% | Return on Equity (TTM) -780.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 179565751 | Price to Sales(TTM) 77.32 |
Enterprise Value 179565751 | Price to Sales(TTM) 77.32 | ||
Enterprise Value to Revenue 81.44 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 84994304 | Shares Floating 53456569 |
Shares Outstanding 84994304 | Shares Floating 53456569 | ||
Percent Insiders 3.37 | Percent Institutions 20.22 |
Upturn AI SWOT
Milestone Pharmaceuticals Inc
Company Overview
History and Background
Milestone Pharmaceuticals Inc. (formerly Milestone Medical Inc.) is a biopharmaceutical company focused on developing and commercializing etripamil for cardiovascular indications. Founded in 2003, its primary focus has been on acute cardiac conditions.
Core Business Areas
- Pharmaceutical Development: Development of pharmaceutical products, with a focus on cardiovascular therapeutics, specifically etripamil.
Leadership and Structure
Key leaders include Joseph Oliveto (President and CEO). The organizational structure is typical for a biopharmaceutical company with dedicated teams for R&D, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Etripril Nasal Spray: Etripril is a calcium channel blocker nasal spray being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT). Currently seeking FDA approval. Competitors would be existing antiarrhythmic drugs (e.g., adenosine, verapamil) and other non-pharmacological treatments. Market share for approved product would be new.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and long development timelines. Cardiovascular therapeutics represents a significant segment.
Positioning
Milestone is positioning itself to address an unmet need in PSVT, offering a potentially faster and more convenient treatment option via nasal spray.
Total Addressable Market (TAM)
The TAM for PSVT treatments is estimated to be substantial, given the prevalence of the condition. Etripamil's success depends on FDA approval and market penetration.
Upturn SWOT Analysis
Strengths
- Novel drug delivery method (nasal spray)
- Potential for faster onset of action compared to existing treatments
- Focus on a specific unmet need in cardiovascular medicine
Weaknesses
- Single product focus (etripamil)
- Dependence on regulatory approval
- High R&D expenditure with no current revenue
Opportunities
- Expansion of etripamil to other cardiovascular indications
- Partnerships with larger pharmaceutical companies for commercialization
- Potential for orphan drug designation
Threats
- Regulatory setbacks or rejection of etripamil
- Competition from existing and new PSVT treatments
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BMY
- PFE
- MRK
Competitive Landscape
Milestone's competitive advantage lies in the novel nasal spray delivery, offering a potentially faster and more convenient alternative to existing PSVT treatments. Disadvantages include its single-product focus and dependence on regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Milestone's historical growth is characterized by increased R&D activity and clinical trial progression.
Future Projections: Future growth depends entirely on regulatory approval and commercialization of etripamil. Analyst estimates vary widely based on approval prospects.
Recent Initiatives: Recent initiatives are focused on the etripamil New Drug Application (NDA) submission and preparation for potential commercialization.
Summary
Milestone Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on etripamil for PSVT. Success hinges on regulatory approval and successful commercialization. The company faces threats from competitors and potential setbacks in clinical trials and regulatory processes. Strong advantages include the novel nasal spray delivery system. The single product focus is a major risk factor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data presented may not be exhaustive and is subject to change. Investing in biopharmaceutical companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Milestone Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2019-05-09 | CEO, President & Director Mr. Joseph G. Oliveto M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://www.milestonepharma.com |
Full time employees 33 | Website https://www.milestonepharma.com | ||
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.